Search

Your search keyword '"Quindós, Guillermo"' showing total 540 results

Search Constraints

Start Over You searched for: Author "Quindós, Guillermo" Remove constraint Author: "Quindós, Guillermo"
540 results on '"Quindós, Guillermo"'

Search Results

201. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey.

202. Candidiasis by Candida glabrata , Candida nivariensis and Candida bracarensis in Galleria mellonella : Virulence and Therapeutic Responses to Echinocandins.

203. Virulence of Candida auris from different clinical origins in Caenorhabditis elegans and Galleria mellonella host models.

204. In Vitro Interaction and Killing-Kinetics of Amphotericin B Combined with Anidulafungin or Caspofungin against Candida auris.

205. Candida parapsilosis Colony Morphotype Forecasts Biofilm Formation of Clinical Isolates.

206. Candida duobushaemulonii: An Old But Unreported Pathogen.

207. Utility of two PCR‐RFLP‐based techniques for identification of Candida parapsilosis complex blood isolates.

208. Prevalence and antifungal susceptibility profiles of Candida glabrata, Candida parapsilosis and their close-related species in oral candidiasis.

209. Design and validation of a multiplex PCR protocol for microsatellite typing of Candida parapsilosis sensu stricto isolates.

210. Phytochemical composition, anti-biofilm and anti-quorum sensing potential of fruit, stem and leaves of Salvadora persica L. methanolic extracts.

211. Caries and Candida colonisation in adult patients in Basque Country (Spain).

212. In vitro pharmacodynamic modelling of anidulafungin against Candida spp.

213. Prevalence and antifungal susceptibility patterns of new cryptic species inside the species complexes Candida parapsilosis and Candida glabrata among blood isolates from a Spanish tertiary hospital.

214. Phospholipase and proteinase activities of Candida isolates from denture wearers.

215. In vitro activity of voriconazole against Mexican oral yeast isolates.

216. Isolation of Candida dubliniensis in denture stomatitis

217. Terbinafine susceptibility patterns for onychomycosis-causative dermatophytes and Scopulariopsis brevicaulis

218. In vitro activities of carvacrol, cinnamaldehyde and thymol against Candida biofilms.

219. In Vitro Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Amphotericin B against Candida auris.

220. Characterization of Yeast Isolated from the Gut Microbiota of Tunisian Children with Autism Spectrum Disorder.

221. Efficacy of the combination of amphotericin B and echinocandins against Candida auris in vitro and in the Caenorhabditis elegans host model.

222. PK/PD modeling and simulation of the in vitro activity of the combinations of isavuconazole with echinocandins against Candida auris.

223. Assessing pH-dependent activities of virulence factors secreted by Candida albicans.

224. Postantifungal Effect of Antifungal Drugs against Candida : What Do We Know and How Can We Apply This Knowledge in the Clinical Setting?

225. In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida : A European Study.

228. Caenorhabditis elegans as a Model System To Assess Candida glabrata, Candida nivariensis , and Candida bracarensis Virulence and Antifungal Efficacy.

229. Fungal co-infection in COVID-19 patients: Should we be concerned?

230. Killing kinetics of anidulafungin, caspofungin and micafungin against Candida parapsilosis species complex: Evaluation of the fungicidal activity.

231. [Epidemiology of invasive mycoses: A landscape in continuous change].

232. The continuous changes in the aetiology and epidemiology of invasive candidiasis: from familiar Candida albicans to multiresistant Candida auris.

233. Oral Candida colonization in patients with chronic periodontitis. Is there any relationship?

234. Usefulness of the Non-conventional Caenorhabditis elegans Model to Assess Candida Virulence.

236. EPICO 4.0. 'Total quality' in the management of invasive candidiasis in critically ill patients by analysing the integrated process.

237. In Vitro Antifungal Susceptibility of Oral Candida Isolates from Patients Suffering from Caries and Chronic Periodontitis.

238. Vancomycin heteroresistant community associated methicillin-resistant Staphylococcus aureus ST72-SCCmecIVa strain colonizing the nostrils of a five-year-old Spanish girl.

239. Detection and characterization of surface microbial contamination in emergency ambulances.

240. EPICO 3.0. Management of non-neutropenic patients in medical wards.

242. [Current aspects of invasive diseases caused by Candida and other yeast fungi].

243. [Clinical usefulness of triazole derivatives in the management of fungal infections].

244. [State of the art in invasive diseases by filamentous fungi].

246. Epidemiology of candidaemia and invasive candidiasis. A changing face.

247. [Presence of Candida in recurrent aphthous stomatitis].

248. Sertaconazole: an antifungal agent for the topical treatment of superficial candidiasis.

249. [Invasive fungal disease: conventional or molecular mycological diagnosis?].

250. In vitro activities of new triazole antifungal agents, posaconazole and voriconazole, against oral Candida isolates from patients suffering from denture stomatitis.

Catalog

Books, media, physical & digital resources